Suppr超能文献

酒精性肝硬化中的血清簇集素和玻连蛋白

Serum clusterin and vitronectin in alcoholic cirrhosis.

作者信息

Høgåsen K, Homann C, Mollnes T E, Graudal N, Høgåsen A K, Hasselqvist P, Thomsen A C, Garred P

机构信息

Institute of Immunology and Rheumatology, National Hospital, University of Oslo, Norway; Oslo, Norway.

出版信息

Liver. 1996 Apr;16(2):140-6. doi: 10.1111/j.1600-0676.1996.tb00719.x.

Abstract

Clusterin and vitronectin are multifunctional regulatory proteins which both serve as complement lysis inhibitors. Previous data have strongly suggested that serum vitronectin is mainly produced in the liver, whereas the biosynthetic origin for serum clusterin has not been determined. In the present study we aimed to determine the role of the liver in producing these proteins and to evaluate the proteins as possible markers of liver failure. We therefore quantified clusterin and vitronectin in serum from patients suffering from alcoholic liver cirrhosis (n = 83), and in serum-free culture supernatants from the hepatoma cell line HepG2. The median clusterin concentration was 0.20 g/l in cirrhosis and 0.37 g/l in the controls, whereas corresponding vitronectin values were 0.19 and 0.26 g/l, respectively. The concentration of both proteins showed significant correlation (p < 0.0001) with disease severity and with established plasma markers of hepatic synthetic function, such as albumin and prothrombin complex. The clusterin level, but not the vitronectin level, correlated with survival (p = 0.005). The rates of synthesis of clusterin, vitronectin and C3 from HepG2 cells were 0.02, 0.21 and 1.9 micrograms/10(6) cells/24 h, respectively. From the present data we conclude that clusterin (as vitronectin and C3) is mainly produced in the liver and may be a useful marker in the evaluation of severity of liver disease and prognosis of patients with alcoholic cirrhosis.

摘要

聚集素和玻连蛋白是多功能调节蛋白,二者均作为补体溶解抑制剂。既往数据强烈提示血清玻连蛋白主要由肝脏产生,而血清聚集素的生物合成来源尚未确定。在本研究中,我们旨在确定肝脏在产生这些蛋白中的作用,并评估这些蛋白作为肝衰竭潜在标志物的可能性。因此,我们对酒精性肝硬化患者(n = 83)的血清以及肝癌细胞系HepG2无血清培养上清液中的聚集素和玻连蛋白进行了定量分析。肝硬化患者血清聚集素浓度中位数为0.20 g/l,对照组为0.37 g/l,而相应的玻连蛋白值分别为0.19 g/l和0.26 g/l。两种蛋白的浓度均与疾病严重程度以及肝脏合成功能的既定血浆标志物(如白蛋白和凝血酶原复合物)显著相关(p < 0.0001)。聚集素水平与生存率相关(p = 0.005),而玻连蛋白水平则无此相关性。HepG2细胞中聚集素、玻连蛋白和C3的合成速率分别为0.02、0.21和1.9微克/10⁶细胞/24小时。根据目前的数据,我们得出结论:聚集素(与玻连蛋白和C3一样)主要在肝脏产生,可能是评估酒精性肝硬化患者疾病严重程度和预后的有用标志物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验